CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The PRIME project focuses on treating epilepsy by engineering human cells to respond to specific RNA fragments that signal impending seizures. This approach aims to release a therapeutic factor preemptively, potentially transforming treatment for drug-resistant epilepsy and other neurological disorders.
There remain urgent and unmet needs for the treatment of neurological diseases.
Epilepsy is a serious, chronic brain disease characterized by recurrent seizures.
Closed-loop, implanted devices offer ways to reduce seizures in drug-resistant patients but their efficacy is poor and they interrupt seizures only after they begin. PRIME capitalizes on a breakthrough discovery that transfer RNA (tRNA) fragments, a novel class of noncoding RNA, increase in patients in advance of when a seizure occurs.…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Denmark, Aarhus C
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Denmark, Aarhus N
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
ROYAL COLLEGE OF SURGEONS IN IRELAND
Ireland, Dublin
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Italy, Ferrara
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
